Captrust Financial Advisors Buys 169 Shares of Revvity, Inc. (NYSE:RVTY)

Captrust Financial Advisors raised its position in shares of Revvity, Inc. (NYSE:RVTY) by 0.2% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 99,450 shares of the company’s stock after acquiring an additional 169 shares during the period. Captrust Financial Advisors owned approximately 0.08% of Revvity worth $12,705,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Rothschild Investment LLC bought a new stake in Revvity in the 2nd quarter valued at $25,000. Gladius Capital Management LP bought a new stake in shares of Revvity in the third quarter valued at about $32,000. EverSource Wealth Advisors LLC grew its stake in shares of Revvity by 74.2% in the second quarter. EverSource Wealth Advisors LLC now owns 392 shares of the company’s stock valued at $41,000 after acquiring an additional 167 shares in the last quarter. Family Firm Inc. bought a new position in Revvity during the second quarter worth about $43,000. Finally, Fairfield Financial Advisors LTD acquired a new stake in Revvity in the 2nd quarter worth about $43,000. Institutional investors and hedge funds own 86.65% of the company’s stock.

Insider Buying and Selling

In related news, insider Tajinder S. Vohra sold 2,154 shares of the firm’s stock in a transaction on Wednesday, October 9th. The stock was sold at an average price of $121.73, for a total transaction of $262,206.42. Following the completion of the transaction, the insider now directly owns 19,652 shares of the company’s stock, valued at $2,392,237.96. This trade represents a 9.88 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 0.60% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the stock. Wells Fargo & Company assumed coverage on shares of Revvity in a research report on Tuesday, August 27th. They issued an “equal weight” rating and a $130.00 price target for the company. Robert W. Baird upped their target price on Revvity from $136.00 to $138.00 and gave the company an “outperform” rating in a research report on Tuesday, November 5th. Raymond James raised their price target on Revvity from $144.00 to $146.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 5th. Sanford C. Bernstein cut their price objective on shares of Revvity from $150.00 to $145.00 and set an “outperform” rating for the company in a research report on Tuesday, November 5th. Finally, Barclays decreased their target price on shares of Revvity from $140.00 to $135.00 and set an “overweight” rating on the stock in a report on Monday, November 25th. Seven research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $131.73.

Revvity Stock Performance

Shares of Revvity stock opened at $116.14 on Monday. The company’s 50 day moving average price is $119.71 and its two-hundred day moving average price is $116.09. The firm has a market capitalization of $14.13 billion, a P/E ratio of 56.11, a P/E/G ratio of 3.57 and a beta of 1.05. Revvity, Inc. has a fifty-two week low of $87.58 and a fifty-two week high of $129.50. The company has a debt-to-equity ratio of 0.40, a current ratio of 3.56 and a quick ratio of 2.97.

Revvity (NYSE:RVTY) last issued its quarterly earnings data on Monday, November 4th. The company reported $1.28 earnings per share for the quarter, topping analysts’ consensus estimates of $1.13 by $0.15. The business had revenue of $684.10 million for the quarter, compared to analyst estimates of $679.66 million. Revvity had a return on equity of 7.42% and a net margin of 9.34%. Revvity’s quarterly revenue was up 2.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.18 EPS. On average, equities analysts forecast that Revvity, Inc. will post 4.85 earnings per share for the current fiscal year.

Revvity declared that its board has approved a share buyback program on Monday, November 4th that authorizes the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization authorizes the company to purchase up to 6.5% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company’s board of directors believes its shares are undervalued.

Revvity Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, February 7th. Investors of record on Friday, January 17th will be issued a $0.07 dividend. The ex-dividend date of this dividend is Friday, January 17th. This represents a $0.28 dividend on an annualized basis and a yield of 0.24%. Revvity’s dividend payout ratio (DPR) is presently 13.53%.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.